Login / Signup

Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.

Gunavanthi D BoorgulaTawanda GumboSanjay SinghPamela J McShaneJulie V PhilleyShashikant Srivastava
Published in: Tuberculosis (Edinburgh, Scotland) (2024)
Use of 0.5 % oxyrase could be a potential solution to reliable and reproducible omadacycline MIC of Mab. However, oxyrase demonstrated a variable effect in reducing MICs against MAC and Mkn.
Keyphrases
  • adverse drug
  • drug induced
  • emergency department
  • risk assessment
  • human health
  • monoclonal antibody